Payment overview · 2025
General Payments
$969.18
64 reported records · 14 companies
Healthcare provider profile · identity verified
Vashist Nobbee, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ROANOKE, VA · NPI 1265411573
Verified facts
What the public records show
CMS Open Payments records show Vashist Nobbee, MD received $969.18 in general payments during 2025 across 64 reported records.
Novo Nordisk Inc accounted for 25.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $249.77 | 25.8% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $185.18 | 19.1% | 15 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $139.32 | 14.4% | 16 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $77.17 | 8.0% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $58.83 | 6.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $52.87 | 5.5% | 3 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $34.85 | 3.6% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.71 | 3.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.81 | 3.2% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $30.56 | 3.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.02 | 2.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.65 | 2.1% | 1 | 2025 |
| The Binding Site Inc. | Unresolved — no canonical attribution shown | $18.58 | 1.9% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.86 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $969.18 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $139.32 | 16 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $139.32 | 16 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $118.63 | 11 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $116.02 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $109.77 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $79.76 | 5 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $77.17 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $66.55 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $58.83 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $46.13 | 2 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $34.85 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $33.71 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.13 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $30.56 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.65 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| Freelite Normalized: freelite |
Device | The Binding Site Inc. | $18.58 | 2 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
67 | 17 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
126 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
126 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
49 | 48 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 583 | 164 |
| Levothyroxine Sodium | Levothyroxine Sodium | 530 | 136 |
| Amlodipine Besylate | Amlodipine Besylate | 437 | 118 |
| Lisinopril | Lisinopril | 395 | 98 |
| Omeprazole | Omeprazole | 392 | 112 |
| Alprazolam | Alprazolam | 381 | 88 |
| Losartan Potassium | Losartan Potassium | 368 | 98 |
| Simvastatin | Simvastatin | 349 | 95 |
| Hydrochlorothiazide | Hydrochlorothiazide | 331 | 86 |
| Metformin Hcl | Metformin Hcl | 280 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 266 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 262 | 69 |
| Gabapentin | Gabapentin | 227 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 226 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 202 | 60 |
| Prednisone | Prednisone | 202 | 115 |
| Glipizide Er | Glipizide | 198 | 50 |
| Allopurinol | Allopurinol | 197 | 51 |
| Azithromycin | Azithromycin | 183 | 145 |
| Furosemide | Furosemide | 181 | 54 |
| Meloxicam | Meloxicam | 180 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 177 | 48 |
| Potassium Chloride | Potassium Chloride | 176 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 167 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 141 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 140 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 134 | 23 |
| Tramadol Hcl | Tramadol Hcl | 129 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 128 | 24 |
| Sertraline Hcl | Sertraline Hcl | 127 | 36 |
| Eliquis | Apixaban | 126 | 26 |
| Lorazepam | Lorazepam | 125 | 26 |
| Bupropion Xl | Bupropion Hcl | 117 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 110 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 107 | 86 |
| Trazodone Hcl | Trazodone Hcl | 107 | 28 |
| Clonazepam | Clonazepam | 102 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 100 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 94 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 92 | 21 |
| Enalapril Maleate | Enalapril Maleate | 90 | 26 |
| Famotidine | Famotidine | 85 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 85 | 26 |
| Warfarin Sodium | Warfarin Sodium | 84 | 18 |
| Carvedilol | Carvedilol | 81 | 20 |
| Alendronate Sodium | Alendronate Sodium | 80 | 24 |
| Klor-Con M20 | Potassium Chloride | 75 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 71 | 58 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 69 | 19 |
| Synthroid | Levothyroxine Sodium | 67 | 17 |
| Montelukast Sodium | Montelukast Sodium | 65 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 63 | 57 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 18 |
| Ozempic | Semaglutide | 61 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 61 | 13 |
| Rizatriptan | Rizatriptan Benzoate | 58 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 56 | 44 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 21 |
| Valacyclovir | Valacyclovir Hcl | 53 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 51 | 25 |
| Mirtazapine | Mirtazapine | 51 | 11 |
| Fenofibrate | Fenofibrate | 50 | 15 |
| Glimepiride | Glimepiride | 49 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 49 | 48 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 13 |
| Spironolactone | Spironolactone | 48 | 15 |
| Pregabalin | Pregabalin | 47 | suppressed |
| Celecoxib | Celecoxib | 46 | 11 |
| Glipizide | Glipizide | 46 | suppressed |
| Diazepam | Diazepam | 45 | 17 |
| Meclizine Hcl | Meclizine Hcl | 45 | 24 |
| Metformin Hcl Er | Metformin Hcl | 44 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | 11 |
| Clonidine Hcl | Clonidine Hcl | 42 | 13 |
| Ezetimibe | Ezetimibe | 41 | 13 |
| Jardiance | Empagliflozin | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Ramipril | Ramipril | 39 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 39 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | 12 |
| Atenolol | Atenolol | 38 | 11 |
| Gemfibrozil | Gemfibrozil | 37 | 12 |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Irbesartan | Irbesartan | 36 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | 12 |
| Buspirone Hcl | Buspirone Hcl | 33 | 11 |
| Promethazine Hcl | Promethazine Hcl | 33 | 12 |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Klor-Con M10 | Potassium Chloride | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Indapamide | Indapamide | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 17 |
| Diltiazem 12hr Er | Diltiazem Hcl | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Epinephrine | Epinephrine | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 13 |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 13 |
| Clindamycin Hcl | Clindamycin Hcl | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Triazolam | Triazolam | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | 11 |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $969.18 · 64 records | Novo Nordisk Inc | ABRYSVO, AFREZZA, COMIRNATY, Dexcom G6 Transmitter, EVENITY, FUROSCIX, Freelite, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, VRAYLAR, Wegovy, XHANCE, XIFAXAN, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error